AI Verdict
VRTX has stronger fundamentals based on our AI analysis.
MRK vs VRTX Fundamental Comparison
| Metric | MRK | VRTX |
|---|---|---|
| Revenue | $65.0B | $12.0B |
| Net Income | $18.3B | $4.0B |
| Net Margin | 28.1% | 32.9% |
| ROE | 34.7% | 21.2% |
| ROA | 13.3% | 15.4% |
| Current Ratio | 1.54x | 2.90x |
| Debt/Equity | 0.89x | 0.01x |
| EPS | $7.28 | $15.32 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MRK vs VRTX: Frequently Asked Questions
Is MRK or VRTX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), VRTX has stronger fundamentals. MRK is rated BUY (80% confidence) while VRTX is rated BUY (86% confidence). This is not investment advice.
How does MRK compare to VRTX fundamentally?
Merck & Co., Inc. has ROE of 34.7% vs VERTEX PHARMACEUTICALS INC / MA's 21.2%. Net margins are 28.1% vs 32.9% respectively.
Which stock pays higher dividends, MRK or VRTX?
MRK has a dividend yield of N/A or no dividend while VRTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MRK or VRTX for long term?
For long-term investing, consider that MRK has BUY rating with 80% confidence, while VRTX has BUY rating with 86% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MRK vs VRTX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MRK vs VRTX, the AI consensus favors VRTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.